Answers are grounded in this paper and cite their sources.
Objective. To assess the consequences of COVID-19 in 3—7 months after discharge according to clinical, instrumental and laboratory data. Material and methods. The study included patients who underwent inpatient treatment at the COVID-19 center between April 2020 and June 2020. All ones agreed to participate in outpatient examination program «COVID-19 — follow-up study» in 3—7 months after discharge. All patients (n=213) underwent outpatient laboratory examination (general blood test, biochemical blood test, highly sensitive troponin I, highly sensitive C-reactive protein (HCRP), D-dimer, N-terminal fragment of the brain natriuretic hormone precursor (NT-proBNP)), electrocardiography and echocardiography. A 24-hour ECG monitoring and Doppler ultrasound of the lower extremity veins were performed in patients who underwent these procedures in acute period of disease. Contrast-enhanced MRI of the heart was performed in patients whose troponin I concentration was 10-fold higher than the 99th percentile in acute period of disease. Results. The study included 213 patients (55.4% men, median age 57 [49; 64] years). General blood test was normal in most patients. However, mild anemia, neutropenia and lymphopenia were detected in up to 10% of persons. Biochemical blood test revealed high level of NT-proBNP in 70 (32.9%) people, HCRP in 35 (16.4%), D-dimer in 32 (15.1%) and troponin I in 14 (6.6%) patients. GFR <60 ml/min/1.73 m2 was detected in 16 (7.5%) patients, heart rhythm disturbances — in 25 (11.8%) patients, PQ prolongation — in 11 (5.4%) patients, QT prolongation — in 6 (2.8%) cases, bundle branch block — in 47.6% of patients, ST segment depression/elevation — in 33 (15.6%) patients. According to ECG monitoring data, cardiac arrhythmias (atrial fibrillation, non-sustained supraventricular tachycardia and ventricular tachycardia) in acute period of infection were reported in 14 (61%) patients (n=23), after 3—7 months — in 18 (78%) patients. Non-sustained supraventricular tachycardia was more common in post-COVID period (p=0.01). There were no significant pauses or ST segment changes. According to echocardiography data, local contractility disorders were detected in 12 (5.7%) patients. None patient had clinical signs of previous myocarditis. According to contrast-enhanced MRI (n=5), no data on acute myocarditis and post-inflammatory fibrous myocardial changes in long-term period were confirmed in any patient. Doppler ultrasound of lower extremity veins in acute period of infection (n=24) revealed signs of phlebitis in 3 (12.5%) people, post-thrombophlebitis syndrome — in 1 (4.2%) patient, signs of thrombosis — in 2 (8.3%) patients, signs of thrombosis and PTFS — in 1 (4.2%) patient. No venous lesions were found in 70.8% of patients. In long-term period, only one patient had signs of lower extremity vein thrombosis de novo. Conclusion. These data indicate certain changes in patients with previous COVID-19 infection. Further study of post-COVID syndrome, its clinical manifestations and pathophysiological mechanisms is one of the most important objectives.
No takes yet. Share an insight, caveat, or question.
Pogosova et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: